Objective: Urinary tract infection is among the most prevalent infections in humans, and E. coli is the most frequent pathogen causing this disease. The production of Beta lactamase enzymes (ESBL) in this bacterium makes it resistant to many antibiotics. The aim of this study was to evaluate a novel method single daily dose of Amikacin at 48 h intervals in a clinical trial This was a double-blind clinical trial study.Material and Methods: The patients were divided into two groups of Intervention (Administration of single daily dose of Amikacin at 48 h intervals Intervals for 1 week 3 doses) and control (Prescription of Meropenem for 1 Week). Results: The mean age of the Intervention group was (46.64±3.89) and control group (46.03±2.38). The frequency of E. coli infection was 61(54%), and that of other infections was 52(46%).Conclusion: The results of our study show the therapeutic effect of single daily dose administration of Amikacin every 48 hours